Bajaj HealthCare Valuation
Is BAJAJHCARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BAJAJHCARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BAJAJHCARE (₹391.5) is trading above our estimate of fair value (₹259.35)
Significantly Below Fair Value: BAJAJHCARE is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BAJAJHCARE?
Key metric: As BAJAJHCARE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BAJAJHCARE's PS Ratio? | |
|---|---|
| PS Ratio | 2.6x |
| Sales | ₹4.76b |
| Market Cap | ₹12.36b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.3x |
| Enterprise Value/EBITDA | 18.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BAJAJHCARE's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.5x | ||
506414 Fermenta Biotech | 2.6x | n/a | ₹9.6b |
539997 Kwality Pharmaceuticals | 2.6x | n/a | ₹9.0b |
506197 Bliss GVS Pharma | 1.7x | n/a | ₹13.8b |
524774 NGL Fine-Chem | 3x | n/a | ₹11.1b |
BAJAJHCARE Bajaj HealthCare | 2.6x | n/a | ₹12.4b |
Price-To-Sales vs Peers: BAJAJHCARE is expensive based on its Price-To-Sales Ratio (2.6x) compared to the peer average (2.5x).
Price to Sales Ratio vs Industry
How does BAJAJHCARE's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Sales vs Industry: BAJAJHCARE is good value based on its Price-To-Sales Ratio (2.6x) compared to the Indian Pharmaceuticals industry average (3.1x).
Price to Sales Ratio vs Fair Ratio
What is BAJAJHCARE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BAJAJHCARE's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Mercury Laboratories
₹1.1b
Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.
538964
₹928.00
7D
-1.7%
1Y
15.6%
Vivimed Labs
₹410.4m
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.
VIVIMEDLAB
₹4.95
7D
0%
1Y
-45.9%
Colinz Laboratories
₹138.6m
Manufactures, markets, and trades in pharmaceutical formulations in India.
531210
₹55.02
7D
-8.8%
1Y
33.1%